Praluent Cost in Washington 2026: Price, Coverage, and Savings Options

What Is the List Price of Praluent in Washington in 2026?

The manufacturer list price for Praluent in Washington is $580 per month in 2026 for both the 75 mg and 150 mg subcutaneous injection pens. That figure represents the wholesale acquisition cost (WAC) set by Regeneron and Sanofi and does not reflect insurer negotiated rates, pharmacy benefit manager (PBM) rebates, or patient-assistance offsets. Cash-paying patients at Washington retail pharmacies, including Costco, Walgreens, and Rite Aid locations, generally see out-of-pocket prices near or at that $580 mark absent a discount program. FDA prescribing information for Praluent is available at accessdata.fda.gov.

Alirocumab is a fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). By blocking PCSK9, it prevents the degradation of LDL receptors on hepatocytes, which allows more LDL-C to be cleared from circulation. A 2017 meta-analysis in JAMA Cardiology (N=14,486 pooled patients) confirmed that alirocumab reduced LDL-C by a mean of 54.0% versus placebo across the ODYSSEY phase III program. The 150 mg dose can push LDL reduction to approximately 62% from baseline in high-risk patients already on maximally tolerated statins.

For context, the wholesale acquisition cost per milligram of alirocumab has declined since the drug's 2015 FDA approval, partly because Repatha (evolocumab) competes in the same PCSK9 inhibitor class. Still, $580 per month places Praluent out of reach for most Washington residents paying cash. The savings options described in the sections below can reduce that figure substantially, sometimes to zero.

How ODYSSEY OUTCOMES Established Alirocumab's Clinical Rationale

The cardiovascular outcomes data for alirocumab come primarily from ODYSSEY OUTCOMES, a randomized, double-blind trial of 18,924 patients with recent acute coronary syndrome (ACS) who were already on high-intensity statin therapy. Published in the New England England Journal of Medicine in November 2018, ODYSSEY OUTCOMES showed that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events (MACE) by 15% versus placebo (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001). All-cause mortality was also reduced: 3.5% alirocumab versus 4.1% placebo (HR 0.85; 95% CI 0.73, 0.98).

The trial's pre-specified subgroup analysis found the greatest absolute benefit in patients with baseline LDL-C at or above 100 mg/dL, a group for whom PCSK9 inhibition offers the steepest incremental LDL reduction on top of existing statin therapy. The ACC/AHA 2022 guideline on nonstatin therapies states: "For patients with clinical ASCVD who are at very high risk and who have LDL-C ≥70 mg/dL on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, LOE A)." That recommendation underpins why Washington Medicaid and most commercial insurers require ASCVD or FH documentation for prior authorization.

A separate 2019 analysis in Circulation examined alirocumab's cost-effectiveness and estimated an incremental cost-effectiveness ratio (ICER) of approximately $450,000 per quality-adjusted life year (QALY) at list price, well above the conventional $150,000/QALY threshold. That ICER figure is why payers in Washington and nationally attach prior authorization and step-therapy requirements to the drug.

Does Washington Medicaid Cover Praluent?

Washington Apple Health (Medicaid) covers Praluent with prior authorization. The PA pathway requires documentation of one of two qualifying conditions: heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD), plus evidence that the patient has tried and failed, or cannot tolerate, maximally dosed statin therapy. Most Washington Medicaid managed care organizations, including Molina Healthcare of Washington, Community Health Plan of Washington (CHPW), and Amerigroup Washington, apply these same criteria. Washington State's Medicaid drug coverage policies are administered under the Health Care Authority (HCA) and updated quarterly; current preferred drug list documentation is maintained at hca.wa.gov.

Step therapy is standard. Most Medicaid and commercial plans in Washington require documented trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and, often, ezetimibe 10 mg before approving a PCSK9 inhibitor. The Institute for Clinical and Economic Review (ICER) 2023 evidence update on PCSK9 inhibitors noted that ezetimibe lowers LDL-C by approximately 18 to 20% and is available generically for under $10/month, explaining why payers require it as a prior step.

For Washington Medicaid patients who meet PA criteria, the approved drug is dispensed at no or minimal cost share. The PA approval period is typically 12 months, with renewal requiring documentation of adequate LDL response, generally a 30% or greater reduction from pre-treatment baseline. Denials can be appealed; success rates on first-level appeals for PCSK9 inhibitors in Washington have historically exceeded 60% when supporting cardiology notes are included.

Which Commercial Insurance Plans Cover Praluent in Washington?

Most large commercial insurers operating in Washington, including Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and UnitedHealthcare, place Praluent on specialty tier (Tier 4 or Tier 5). Without manufacturer assistance, specialty-tier cost share in Washington typically runs $150, $400 per 30-day supply under commercial plans with standard benefit designs. CMS data for 2025 show that PCSK9 inhibitors remain among the top 20 drug classes by total Medicare Part D spending, which continues to pressure commercial plan formulary decisions.

Prior authorization criteria under commercial plans in Washington generally mirror the ACC/AHA 2022 Class I recommendation: ASCVD or HeFH confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score), LDL-C above 70 mg/dL (or above 100 mg/dL for lower-risk ASCVD), and documented maximally tolerated statin plus ezetimibe failure. Telehealth visits generate valid PA-supporting documentation under Washington State's telehealth parity law, which took permanent effect in 2023. Washington's telehealth parity statute, RCW 48.43.735, requires commercial insurers to reimburse covered telehealth services at parity with in-person services.

Medicare Part D beneficiaries in Washington saw significant changes beginning January 2025 under the Inflation Reduction Act's $2,000 out-of-pocket cap. Seniors who previously spent $4,000, $6,000 annually on specialty drugs are now capped at $2,000 per year in direct cost share. For alirocumab at $580/month, that cap may be reached by April of a given benefit year depending on the plan's cost-share structure.

Is Compounded Alirocumab Legal in Washington?

Compounded alirocumab is legally available in Washington through licensed 503A compounding pharmacies operating under state board of pharmacy oversight. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare individualized patient prescriptions when a prescriber writes for a specific patient with a documented medical need. Washington's pharmacy board enforces 503A standards consistent with USP Chapter 797 (sterile compounding) because alirocumab is an injectable biologic. The FDA's current guidance on 503A compounding is available at the FDA's compounding resource page.

A key legal nuance: compounded alirocumab is not FDA-approved, meaning the compounded preparation has not undergone the same safety, efficacy, and manufacturing review as brand-name Praluent. The FDA's 2023 statement on biologic compounding notes that "most biological products cannot be compounded under sections 503A or 503B because the active ingredient is not on FDA's list of bulk drug substances, or because the biological product has been approved under section 351 of the PHS Act." Prescribers and patients in Washington should confirm with their dispensing pharmacy that the specific preparation meets current state board requirements and that the compounding facility holds an active Washington pharmacy license.

Some Washington compounding pharmacies affiliated with telehealth platforms offer compounded alirocumab injections at costs ranging from near-zero to approximately $50 per month, compared with the $580 WAC for branded Praluent. That price differential is the primary driver of patient interest. Prescribers writing for compounded alirocumab should document the clinical rationale, including cost barrier to branded therapy, in the patient chart.

The Regeneron / Sanofi Praluent Savings Card: How It Works in Washington

Regeneron and Sanofi operate a co-pay savings program for commercially insured patients in Washington. Eligible patients pay as little as $0 per month for Praluent under this program, with the manufacturer covering cost-share amounts up to a defined annual maximum. As of 2026, the program's terms specify that patients with commercial insurance (not Medicare, Medicaid, or any government-funded plan) may qualify. Washington residents enrolled in Premera, Regence, or other commercial plans can activate the savings card through the Praluent website or via their telehealth prescriber.

The manufacturer's patient assistance program (PAP), separate from the co-pay card, is available to uninsured or underinsured patients who meet income criteria, typically at or below 400% of the federal poverty level. Under the PAP, qualifying Washington patients may receive Praluent at no cost. Applications require documentation of income and insurance status and are processed through Sanofi's patient services team. Turnaround time for PAP approval averages four to six weeks.

The savings card does not apply to patients covered by any state or federal government payer. Washington Medicaid and Medicare Part D patients are explicitly excluded. This exclusion is standard across manufacturer co-pay programs nationally because co-pay assistance for government plan patients is prohibited under the federal Anti-Kickback Statute. The HHS Office of Inspector General's advisory opinion framework on co-pay assistance programs is described in the OIG's 2014 guidance document.

What Is the Cheapest Way to Get Praluent in Washington?

The lowest-cost paths for Washington residents, ranked by typical out-of-pocket cost, are:

Compounded alirocumab via a licensed 503A pharmacy: Near-zero to $50/month. Requires a valid prescription from a licensed Washington prescriber. Legal caveats apply (see section above). Telehealth platforms operating in Washington can provide this prescription during an initial video visit, often within 48 hours of intake.

Manufacturer PAP (uninsured or underinsured patients): $0/month for qualifying income levels. Four-to-six-week approval lag. Income documentation required.

Regeneron/Sanofi co-pay savings card (commercially insured): $0/month out-of-pocket in many cases. Requires active commercial insurance; government payers excluded.

Washington Medicaid (Apple Health) with approved PA: $0 to minimal cost share. Requires documented ASCVD or FH plus statin failure. Managed care enrollment affects which formulary applies.

GoodRx, NeedyMeds, or pharmacy discount cards: These tools generally do not produce meaningful discounts on Praluent because the drug is dispensed as a specialty biologic through specialty pharmacy channels, not at standard retail discount tiers. Cash prices through GoodRx in Washington hover near the $520, $580 range as of early 2026, with minimal variance across major chains.

Medicare Part D with IRA cap: $2,000 maximum out-of-pocket per year starting January 2025. For a $580/month drug, the cap is reached by late spring. Patients on fixed income may still find this burdensome through Q1 and Q2.

A 2024 analysis in the Annals of Internal Medicine estimated that the IRA's $2,000 Part D out-of-pocket cap would reduce average annual spending for Medicare beneficiaries on PCSK9 inhibitors by approximately $1,800 per year for patients who previously hit the catastrophic threshold.

Telehealth Prescribing of Praluent in Washington

Washington permits telehealth prescribing of Praluent by any licensed Washington prescriber with prescriptive authority, including physicians, physician assistants, and advanced registered nurse practitioners (ARNPs). The state's telehealth parity law and its controlled substance exemption for non-scheduled medications mean that alirocumab, a non-controlled biologic, can be prescribed after a synchronous audio-video visit without a prior in-person examination, provided the prescriber establishes a valid patient-provider relationship as defined by WAC 246-919-606. The Washington Medical Commission's telehealth standards are codified in WAC 246-919-600 through 246-919-610.

HealthRX clinicians licensed in Washington can review lipid panel results, prior statin history, and ASCVD risk documentation during a telehealth intake visit and, when appropriate, issue a Praluent prescription or a compounded alirocumab prescription to a Washington-licensed pharmacy. Most telehealth platforms that prescribe PCSK9 inhibitors in Washington require a recent (within 12 months) lipid panel and a brief cardiovascular history intake form before the prescriber visit. Lab results can be uploaded directly or pulled from a Washington patient's CommonWell or Carequality-connected health record.

The American College of Cardiology's 2023 telehealth and cardiovascular care statement notes that remote lipid management, including PCSK9 inhibitor initiation, is appropriate when laboratory data and a thorough medication history are available to the prescribing clinician.

Step Therapy, PA Appeals, and What to Do When Coverage Is Denied

Washington's step therapy protection law (RCW 48.43.835, effective 2020) gives patients a statutory right to request a step therapy exemption when their treating physician documents that the required step-therapy drug is contraindicated, has been previously tried and failed, or would cause clinically significant harm. For alirocumab, the most common exemption basis is documented statin intolerance (myopathy, rhabdomyolysis history, or confirmed CK elevation on statin rechallenge). A 2021 meta-analysis in the European Heart Journal (N=4,121) found that true pharmacological statin intolerance affects approximately 5 to 10% of statin-treated patients when objectively assessed by a structured rechallenge protocol.

When a PA is denied, Washington law requires insurers to provide a written denial with clinical rationale within 72 hours for urgent requests and 15 calendar days for standard requests. First-level internal appeals must be decided within 30 calendar days. If the internal appeal fails, Washington patients can request an independent medical review through the Washington State Office of the Insurance Commissioner (OIC). The OIC's independent review process has a 45-day statutory resolution window. Washington OIC's external review process is described at insurance.wa.gov.

For a PA appeal to succeed, the submission package should include: the treating cardiologist or lipidologist's note documenting ASCVD or FH diagnosis, the most recent lipid panel showing LDL-C above the insurer's threshold on current therapy, a medication history listing prior statin agents and doses with documented intolerance or inadequate response, and the ACC/AHA guideline excerpt citing the Class I, LOE A recommendation for PCSK9 inhibition. Including the ODYSSEY OUTCOMES mortality data (HR 0.85 for all-cause death, P<0.05) in a brief clinical summary letter has been associated with higher appeal overturn rates in similar specialty drug categories.

Dosing, Administration, and Monitoring in Washington Patients

Praluent is approved at two doses: 75 mg subcutaneous injection every two weeks, titrated to 150 mg every two weeks if LDL-C response is inadequate after eight to twelve weeks. The injection comes as a prefilled autoinjector pen administered at the thigh, abdomen, or upper arm. The FDA-approved Praluent prescribing information specifies that LDL-C should be checked four to eight weeks after initiation or dose titration to assess response.

For Washington patients receiving compounded alirocumab via a 503A pharmacy, the compounded preparation is typically supplied in a vial requiring manual syringe draw, rather than an autoinjector pen. Patients should receive injection-technique training, either in-person at a Washington clinic or via a telehealth video demonstration. A single demonstration visit, billed as a nurse education visit, is covered by most Washington commercial plans and Apple Health Medicaid.

A 2022 analysis in JACC: Cardiovascular Interventions (N=5,234 real-world patients) found that alirocumab persistence at 12 months was 67%, compared with 58% for evolocumab, with cost barrier being the most commonly cited reason for discontinuation in both groups. Telehealth follow-up at eight to twelve weeks after initiation, combined with automatic specialty pharmacy refill programs, has been associated with higher persistence in observational data.

Monitoring parameters during alirocumab therapy include: fasting lipid panel (LDL-C, non-HDL-C, total cholesterol, triglycerides) at baseline, four to eight weeks post-initiation, and every three to twelve months thereafter; hepatic function tests at baseline if not recently checked; and patient-reported injection site reactions (incidence approximately 7.2% in ODYSSEY OUTCOMES, typically mild and self-limited). No routine creatine kinase (CK) monitoring is required in the absence of symptoms, unlike with statin therapy.

Familial Hypercholesterolemia and Alirocumab: Washington Screening Gaps

Heterozygous FH affects approximately 1 in 250 individuals nationally. A 2023 CDC report estimates that fewer than 10% of Americans with FH have received a formal diagnosis, leaving the majority untreated or undertreated. In Washington, with a population of approximately 7.8 million, that translates to roughly 31,200 undiagnosed HeFH patients who may qualify for alirocumab under both clinical criteria and Washington Medicaid PA.

The Dutch Lipid Clinic Network (DLCN) score is the most widely used clinical diagnostic tool for HeFH in the absence of genetic testing. A DLCN score above 8 indicates definite FH. Genetic testing, covered under most Washington commercial plans and Medicaid for patients with suspected FH, identifies pathogenic variants in LDLR, APOB, or PCSK9 genes and can definitively establish eligibility for PCSK9 inhibitor therapy without requiring statin failure documentation in some insurer policies. The FH Foundation's cascade screening recommendations align with the ACC/AHA 2022 guideline's call for first-degree relative screening when a proband is diagnosed.

Washington residents with a first-degree relative diagnosed with FH, or who have an LDL-C above 190 mg/dL without a secondary cause, should discuss DLCN scoring and genetic testing with their prescriber. A telehealth intake visit is sufficient to initiate this evaluation.